Golden
Juventus Therapeutics

Juventus Therapeutics

Juventas Therapeutics is a biotechnology company founded in 2007 that is headquartered in Cleveland, Ohio developing a pipeline of regenerative therapies to treat life-threatening diseases.

Juventas Therapeutics is a biotechnology company developing non-viral gene therapies capable of activating natural processes within the body for healing and repair. The company was founded by Rahul Aras in 2007 and is headquartered in Cleveland, Ohio.

Products

JVS-100

Their first therapeutic product candidate JVS-100 is a non-viral gene therapy expressing a signalling protein that can recruit naturally occurring stem cells and promote tissue repair in a broad range of disease states. Juventas is currently completing a Phase 2b study with JVS-100 in patients with advanced peripheral artery disease.

Funding

Seed

On September 30, 2008 Juventus Therapeutics completed a seed funding round with $300,000 in funding from JumpStart Inc. 

Series A

On October 23, 2008 Juventus Therapeutics completed a series A funding round with $7.7 million in funding from Triathlon Medical Venture Partners and Early Stage Partners. 

Series B

On July 16, 2012 Juventus Therapeutics completed their series B funding round with $22.2 million in funding from Triathlon Medical Venture Partners (lead investor), New Science Ventures (lead investor), Takeda Ventures, Reservoir Venture Partners, North Coast Angel Fund, New Science Ventures, Fletcher Spaght, and Early Stage Partners. 

Timeline

People

Name
Role
Related Golden topics

Joseph Pastore

Senior Vice President, Clinical Product Development



Mathew Pollman

Chief Medical Officer



Michael Fitzgerald

Vice President, Clinical Operations



Rahul Aras

Co-Founder, President, & CEO



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References